OBR – News, Perspective, Catalyst

Today's Oncology News

Opt In Search Archives

U.S. FDA Approves Yescarta® for Relapsed or Refract...

(Gilead) Mar 5, 2021 - Kite, a Gilead Company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approv...

Featured Content

Kristin Ferguson, DNP, RN, OCN, Announces ACCC Virtual Hill Day

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Mazyar Shadman, MD, MPH, Associate Professor, Clinical Research Division Fred Hutchinson Cancer Research Center, discuss clinical highlights in the treatment of CLL from ASH 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Adam Brufsky, MD, PhD, Professor of Medicine, Associate Division Chief for the Division of Hematology/Oncology, UPMC, discuss clinical highlights from SABCS 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Toni Choueiri, MD, Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, discuss clinical progress in renal cell carcinoma (RCC)

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Neeraj Agarwal, MD, Professor of Medicine, Huntsman Cancer Institute, Presidential Endowed Chair of Cancer Research , Co-Leader, HCI Experimental Therapeutics Program, Director, Center of Investigational Therapeutics, Director, Genitourinary Oncology...

At 2021 ASCO GU, big trials like CLEAR, CHECKMATE 274 and EV-301 in renal cell carcinoma and bladder cancer moved the needle on the treatment of challenging urologic cancers. Dive into OBR's wrap-up of some of the most important clinical data from GU21.

Burnout among oncology clinicians has been exacerbated by increased stressors from the pandemic. We look at the causes and effects of this pervasive problem, and find out how ASCO is stepping up to alleviate practice burnout among cancer providers.

At WCLC 2020, the news from Amgen's CodebreaK 100 study was among the pivotal studies showing the great strides being made in lung cancer due to precision medicine. Not every study was a win though - read on to learn more about both the positive and the negative data.

Podcasts

Bladder Cancer – Robert Figlin, MD, and Arjun Balar, MD, discuss clinical progress in bladder cancer

00:00

Listen on
Apple Podcasts

Listen on
Google Play

Listen on
Spotify

Title

Released

Prostate Cancer - Robert Figlin, MD, and Neeraj Agarwal, MD, discuss clinical progress in prostate cancer

02/22/21

Renal Cell Carcinoma (RCC) - Robert Figlin, MD and Toni Choueiri, MD, discuss clinical progress in renal cell carcino...

02/22/21

Breast Cancer – Robert Figlin, MD, and Adam Brufsky, MD, PhD, discuss clinical highlights from SABCS 2020

01/12/21

Chronic Lymphocytic Leukemia (CLL) – Robert Figlin, MD, and Mazyar Shadman, MD, MPH, discuss clinical highlight...

01/11/21

Expert Video Insights

Search by

Peter Voorhees, MD, offers opinion on the role of daratumumab as more trial data emerges

Erika Hamilton, MD, considers the role of NGS testing for breast cancer patients

OBR Green

View Archives

February 2021 Edition

At 2021 ASCO GU, big trials like CLEAR, CHECKMATE 274 and EV-301 in renal cell carcinoma and bladder cancer moved the needle on the treatment of challenging urologic cancers. Dive into O...

February 2021 Edition

Burnout among oncology clinicians has been exacerbated by increased stressors from the pandemic. We look at the causes and effects of this pervasive problem, and find out how ASCO is step...

February 2021 Edition

At WCLC 2020, the news from Amgen's CodebreaK 100 study was among the pivotal studies showing the great strides being made in lung cancer due to precision medicine. Not every study was a...

Blog

New Treatment Directions Unveiled at WCLC 2020

Feb 01, 2021

By Ted Bosworth In early stage non-small cell lung cancer (NSCLC), one source of good news at the 2020 World Conference on Lung Cancer (WCLC 2020) was the effi...

ASH 2020 Advances Immunotherapies, Puts Spotlight on He...

Dec 14, 2020

By Mary Ellen Schneider This year’s annual meeting of the American Society of Hematology (ASH) featured new research on chimeric antigen receptor (CAR) T-cel...

DAY 4: Circulating Tumor Cells, HDAC Inhibition, and Ne...

Dec 11, 2020

by Chase Doyle Day 4 of the 2020 San Antonio Breast Cancer Symposium (SABCS) virtual meeting featured advances in early treatment monitoring, a surprising setb...

OBR Tools

Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontelligence^TM and a customized email alert system summarizing the most recent oncology-specific information available.

Learn More

The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.

Learn More